JP2007536311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007536311A5 JP2007536311A5 JP2007511998A JP2007511998A JP2007536311A5 JP 2007536311 A5 JP2007536311 A5 JP 2007536311A5 JP 2007511998 A JP2007511998 A JP 2007511998A JP 2007511998 A JP2007511998 A JP 2007511998A JP 2007536311 A5 JP2007536311 A5 JP 2007536311A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- agents
- present
- pharmaceutical
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0409921.4A GB0409921D0 (en) | 2004-05-04 | 2004-05-04 | Organic compounds |
| PCT/EP2005/004783 WO2005105727A1 (en) | 2004-05-04 | 2005-05-03 | Crth2 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007536311A JP2007536311A (ja) | 2007-12-13 |
| JP2007536311A5 true JP2007536311A5 (https=) | 2008-06-19 |
Family
ID=32482645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511998A Pending JP2007536311A (ja) | 2004-05-04 | 2005-05-03 | Ｃｒｔｈ２受容体アンタゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080269335A1 (https=) |
| EP (1) | EP1756032A1 (https=) |
| JP (1) | JP2007536311A (https=) |
| KR (1) | KR20070015562A (https=) |
| CN (1) | CN1950323A (https=) |
| AU (1) | AU2005238199B2 (https=) |
| BR (1) | BRPI0510606A (https=) |
| CA (1) | CA2563454A1 (https=) |
| GB (1) | GB0409921D0 (https=) |
| MX (1) | MXPA06012664A (https=) |
| RU (1) | RU2006142738A (https=) |
| WO (1) | WO2005105727A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| UY29223A1 (es) | 2004-11-23 | 2006-06-30 | Astrazeneca Ab | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación |
| EP1937632A1 (en) | 2005-10-06 | 2008-07-02 | Astra Zeneca AB | Novel compounds |
| TW200745003A (en) * | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| TW200732296A (en) * | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Novel compounds |
| UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
| DK2229358T3 (da) | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
| BRPI0907364A2 (pt) | 2008-02-01 | 2015-07-14 | Amira Pharmaceuticals Inc | Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina |
| WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
| JP2011513242A (ja) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体アンタゴニスト |
| US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
| US8071807B2 (en) | 2008-07-03 | 2011-12-06 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
| WO2010039977A2 (en) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
| WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| WO2011002814A2 (en) * | 2009-06-30 | 2011-01-06 | Ligand Pharmaceuticals Inc. | Biaryl oxyacetic acid compounds |
| EP2461809A4 (en) | 2009-07-31 | 2013-06-19 | Panmira Pharmaceuticals Llc | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES |
| US8815917B2 (en) | 2009-08-05 | 2014-08-26 | Panmira Pharmaceuticals, Llc | DP2 antagonist and uses thereof |
| EP2521713A4 (en) | 2010-01-06 | 2013-10-02 | Panmira Pharmaceuticals Llc | ANTAGONIST OF DP2 AND ITS USES |
| CN102958914B (zh) * | 2010-07-05 | 2015-05-27 | 埃科特莱茵药品有限公司 | 1-苯基取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途 |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| TW201331179A (zh) | 2011-12-21 | 2013-08-01 | Actelion Pharmaceuticals Ltd | 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途 |
| CA2876808A1 (en) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| MX389242B (es) | 2015-06-15 | 2025-03-20 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| TWI794369B (zh) | 2017-12-14 | 2023-03-01 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TWI780281B (zh) | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TW201927738A (zh) | 2017-12-14 | 2019-07-16 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| CN114502164B (zh) * | 2019-05-22 | 2024-01-26 | 石药集团中奇制药技术（石家庄）有限公司 | 杂环化合物及其盐的应用 |
| BR112021025637A2 (pt) | 2019-06-19 | 2022-02-01 | Nmd Pharma As | Compostos para o tratamento de doenças neuromusculares |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2039490A1 (de) * | 1970-08-08 | 1972-02-24 | Agfa Gevaert Ag | Fotografisches farbkupplerhaltiges Material |
| DE2039489C3 (de) * | 1970-08-08 | 1979-08-09 | Agfa-Gevaert Ag, 5090 Leverkusen | Farbfotografisches Aufzeichnungsmaterial |
| CH585687A5 (https=) * | 1972-08-24 | 1977-03-15 | Ciba Geigy Ag | |
| DE2503223A1 (de) * | 1974-02-05 | 1975-08-07 | Sandoz Ag | Verfahren zur herstellung neuer carbocyclischer verbindungen |
| FR2567514B1 (fr) * | 1984-07-13 | 1987-08-28 | Najer Henry | Nouveaux ether-oxydes derives de cyclopropylphenols |
| US6376546B1 (en) * | 1997-10-14 | 2002-04-23 | Asahi Kasei Kabushiki Kaisha | Biphenyl-5-alkanoic acid derivatives and use thereof |
| JPH11263752A (ja) * | 1998-01-12 | 1999-09-28 | Honshu Chem Ind Co Ltd | ヒドロ芳香族オキシ酢酸ｔ―ブチルエステル |
| CA2331056A1 (en) * | 1998-05-12 | 1999-12-02 | Wyeth | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia |
| DE60325830D1 (de) * | 2002-02-21 | 2009-03-05 | Asahi Kasei Pharma Corp | Substituiertes phenylalkansäurederivat und dessen verwendung |
| US6867320B2 (en) * | 2002-02-21 | 2005-03-15 | Asahi Kasei Pharma Corporation | Substituted phenylalkanoic acid derivatives and use thereof |
| WO2004094386A1 (en) * | 2003-03-28 | 2004-11-04 | Eli Lilly And Company | Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b) |
| SE0301009D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| CA2535665A1 (en) * | 2003-08-14 | 2005-02-24 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivative and use thereof |
-
2004
- 2004-05-04 GB GBGB0409921.4A patent/GB0409921D0/en not_active Ceased
-
2005
- 2005-05-03 CN CNA2005800143644A patent/CN1950323A/zh active Pending
- 2005-05-03 WO PCT/EP2005/004783 patent/WO2005105727A1/en not_active Ceased
- 2005-05-03 AU AU2005238199A patent/AU2005238199B2/en not_active Ceased
- 2005-05-03 CA CA002563454A patent/CA2563454A1/en not_active Abandoned
- 2005-05-03 BR BRPI0510606-0A patent/BRPI0510606A/pt not_active IP Right Cessation
- 2005-05-03 US US11/568,464 patent/US20080269335A1/en not_active Abandoned
- 2005-05-03 RU RU2006142738/04A patent/RU2006142738A/ru not_active Application Discontinuation
- 2005-05-03 JP JP2007511998A patent/JP2007536311A/ja active Pending
- 2005-05-03 EP EP05741318A patent/EP1756032A1/en not_active Withdrawn
- 2005-05-03 KR KR1020067023085A patent/KR20070015562A/ko not_active Withdrawn
- 2005-05-03 MX MXPA06012664A patent/MXPA06012664A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007536311A5 (https=) | ||
| Das et al. | A survey of the structures of US FDA approved combination drugs | |
| Cui et al. | Efficacy and safety of long‐term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction | |
| US20190216779A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
| JP2006508953A5 (https=) | ||
| WO2005065646A3 (en) | Novel drug compositions and dosage forms | |
| WO2006058249A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
| ATE339954T1 (de) | Kombinationen von formoterol und tiotropium-salz | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2004105694A3 (en) | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | |
| JP2015524444A5 (https=) | ||
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
| EE05404B1 (et) | Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nhtud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon | |
| WO2008064192A3 (en) | Modified release analgesic suspensions | |
| JP2009530413A5 (https=) | ||
| JP2005537268A5 (https=) | ||
| WO2006008639A8 (en) | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody | |
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| WO2007106550A3 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
| JP2006500346A5 (https=) | ||
| GT200900089A (es) | Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine | |
| US20060004076A1 (en) | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | |
| WO2005044186A3 (en) | Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same |